10-QPeriod: Q2 FY2009

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2009

Filed August 3, 2009For Securities:DXCM

Summary

This 10-Q filing for DexCom, Inc. (DXCM) for the period ended June 30, 2009, indicates a company in its early commercialization phase with significant ongoing investment in research and development. The company is focused on its continuous glucose monitoring (CGM) systems, having recently launched its third-generation SEVEN PLUS system. While product revenue is growing, it remains insufficient to cover operational costs, resulting in continued net losses and an accumulated deficit. Key financial highlights include a significant increase in cash and cash equivalents and marketable securities driven by a successful follow-on public offering in February 2009, which provided substantial financing. However, the company also carries a significant amount of long-term debt, including convertible senior notes, which impact interest expense. Despite the ongoing losses, the company believes it has sufficient liquidity for at least the next twelve months, supported by its current cash reserves and projected contributions from partnerships.

Key Highlights

  • 1Product revenues increased to $4.1 million in Q2 2009 from $1.9 million in Q2 2008, and to $6.8 million in the first six months of 2009 from $3.8 million in the same period of 2008.
  • 2The company generated substantial net proceeds of approximately $45.6 million from a follow-on public offering of common stock in February 2009.
  • 3Net cash used in operating activities decreased to $20.4 million for the first six months of 2009 from $28.4 million in the same period of 2008.
  • 4Despite revenue growth, the company reported a net loss of $15.3 million for Q2 2009 and $28.5 million for the first six months of 2009.
  • 5As of June 30, 2009, the company had $4.2 million in cash and cash equivalents and $44.7 million in short-term marketable securities.
  • 6Long-term debt, including $60 million in convertible senior notes, remains a significant financial obligation.
  • 7The company is actively involved in patent litigation with Abbott Diabetes Care, Inc. regarding alleged infringement of continuous glucose monitor patents.

Frequently Asked Questions

DexCom is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. They recently launched their third-generation CGM system, the SEVEN PLUS, in Q1 2009, and are also developing an in-hospital CGM system.

Product revenue is showing growth, with a significant increase in Q2 2009 and the first six months of 2009 compared to the prior year. However, the company continues to incur substantial net losses and has an accumulated deficit, indicating that revenues are not yet sufficient to cover operational and development expenses.

DexCom has $4.2 million in cash and $44.7 million in marketable securities as of June 30, 2009. A successful follow-on public offering in February 2009 provided approximately $45.6 million in net proceeds. The company believes its current liquidity is sufficient for at least the next twelve months.

Key risks include the need for market acceptance of its products, ongoing dependence on third-party payor reimbursement, intense competition from established medical device companies, significant debt obligations, and ongoing patent litigation with Abbott Diabetes Care.